Compared side by side
Semaglutide vs Semaglutide (oral): how they differ
The short answer
They are the same GLP-1 receptor agonist, as a weekly injection or as a daily tablet made with an absorption enhancer (SNAC). The tablet label puts absorption at about 0.4–2% of each tablet, which is why tablet doses run in whole milligrams while the weekly shot is a fraction of one. Both are FDA-approved: the shot as Ozempic and Wegovy, the tablets as Rybelsus and Ozempic tablets for type 2 diabetes and as Wegovy tablets for weight management.
Side by side
| Compared | Semaglutide | Semaglutide (oral) |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Ozempic, Wegovy | Rybelsus, Wegovy pill, Ozempic pill, Oral semaglutide |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | Semaglutide as a daily tablet instead of a weekly shot, FDA-approved as Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) for type 2 diabetes and as Wegovy tablets (up to 25 mg) for weight management. |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | The same GLP-1 receptor agonist as the weekly injection, made into a daily tablet with an absorption enhancer (SNAC). The Rybelsus and Ozempic tablet label puts absorption at about 0.4–2% of each tablet, which is why tablet doses run in whole milligrams while the weekly shot is a fraction of one. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | The strict morning routine is the hardest part, and nausea after each dose step feels much like the injection. Each line has its own dose steps, so log the strength on your pack. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | FDA label: 1.5–25 mg, starting dose 1.5 mg. |
| How often | Weekly SubQ | Daily |
| Half-life | ~1 week (FDA label) | ~1 week |
| Route | SubQ injection | Oral tablet |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | Not in our library |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation |
- Category
- SemaglutideMetabolic & GLP-1
- Semaglutide (oral)Metabolic & GLP-1
- Also known as
- SemaglutideOzempic, Wegovy
- Semaglutide (oral)Rybelsus, Wegovy pill, Ozempic pill, Oral semaglutide
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- Semaglutide (oral)Semaglutide as a daily tablet instead of a weekly shot, FDA-approved as Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) for type 2 diabetes and as Wegovy tablets (up to 25 mg) for weight management.
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- Semaglutide (oral)The same GLP-1 receptor agonist as the weekly injection, made into a daily tablet with an absorption enhancer (SNAC). The Rybelsus and Ozempic tablet label puts absorption at about 0.4–2% of each tablet, which is why tablet doses run in whole milligrams while the weekly shot is a fraction of one.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- Semaglutide (oral)The strict morning routine is the hardest part, and nausea after each dose step feels much like the injection. Each line has its own dose steps, so log the strength on your pack.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- Semaglutide (oral)FDA label: 1.5–25 mg, starting dose 1.5 mg.
- How often
- SemaglutideWeekly SubQ
- Semaglutide (oral)Daily
- Half-life
- Semaglutide~1 week (FDA label)
- Semaglutide (oral)~1 week
- Route
- SemaglutideSubQ injection
- Semaglutide (oral)Oral tablet
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- Semaglutide (oral)Not in our library
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- Semaglutide (oral)Established: clinical trials or FDA-approved use exists
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- Semaglutide (oral)Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation
Typical run: Community practice — opinions vary. Not a clinical recommendation. “Not in our library” means the entry doesn’t hold it.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Semaglutide (oral)
Week-by-week cards for Semaglutide (oral) are not in our library.
Questions people ask
How long do semaglutide and Semaglutide (oral) last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of Semaglutide (oral) is ~1 week.
How often are semaglutide and Semaglutide (oral) taken?
Semaglutide: weekly SubQ. Route: SubQ injection. Semaglutide (oral): daily. Route: Oral tablet.
How are semaglutide and Semaglutide (oral) dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The FDA label range for Semaglutide (oral) is 1.5–25 mg, with a 1.5 mg starting dose.
What are the common side effects of semaglutide and Semaglutide (oral)?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For Semaglutide (oral): nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation.